$IOVA - On our trading list. This one has had a good year and has a lot of potential. A high risk/high reward biotech play.JMP Securities analyst Reni Benjamin initiated coverage of Iovance Biotherapeutics with an Outperform rating and $38 price target.The analyst cites the company's multiple ongoing pivotal trials in melanoma and cervical cancer, noting that the clinical data from its earlier trials demonstrated "impressive efficacy." Benjamin adds that Iovance is also conducting tumor infiltrating lymphocytes, or TIL, trials in head/ neck cancer and non-small cell lung cancer as well as other indications. $IOVA, Iovance Biotherapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page